



## **Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference**

September 6, 2022

DURHAM, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a pre-recorded corporate presentation at the H.C. Wainwright 24th Annual Global Investment Conference made available on Monday, September 12, 2022 at 7:00 a.m. ET.

An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at [ir.chimerix.com](http://ir.chimerix.com), where it will be archived for approximately 90 days.

### **About Chimerix**

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company's most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

#### **CONTACT:**

Investor Relations:

Michelle LaSpaluto

919 972-7115

[ir@chimerix.com](mailto:ir@chimerix.com)

Will O'Connor

Stern Investor Relations

212-362-1200

[will@sternir.com](mailto:will@sternir.com)



Source: Chimerix, Inc.